2025-524160-38-00招募中3 期
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 75
- 试验地点
- 23
- 主要终点
- Overall survival (OS)
研究概览
简要总结
To assess OS in Cohort A and Cohort B
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study
排除标准
- •Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically stable
- •Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been resumed in the parent study, the participant is eligible to enroll
研究组 & 干预措施
Lenvatinib, Lenvatinib
Test
干预措施: Lenvatinib (Drug)
Belzutifan
Test
干预措施: Belzutifan (Drug)
结局指标
主要结局
Overall survival (OS)
Overall survival (OS)
次要结局
- Number of Participants Who Experience One or More Adverse Events (AEs)
- Number of Participants Who Discontinue Study Treatment Due to AEs
研究者
Karla Rodriguez-Lopez
Scientific
Merck Sharp & Dohme LLC
研究点 (23)
Loading locations...
相似试验
尚未招募
不适用
Extension Study for Participants in Studies That Include Belzutifanadvanced solid tumors or von Hippel-Lindau-related neoplasmsjRCT20612600084
招募中
3 期
Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Eliglustat Sublingual Film in Patients with Gaucher Disease Type 1 and Type 3.CTRI/2024/08/072953Amneal Pharmaceuticals Pvt Ltd30
招募中
1 期
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors2025-521702-18-00Novartis Pharma AG27
招募中
1 期
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesChronic Inflammatory Demyelinating PolyneuropathyMyasthenia GravisMultiple SclerosisNCT07304154Kite, A Gilead Company52
已完成
4 期
A clinical trial to evaluate the immunological non-interference of typhoid Vi conjugate vaccine with yellow fever vaccine administered to healthy subjectsCTRI/2024/01/061080Zydus Lifesciences Limited714